SLC1A5 and chondrosarcoma: The MEK, ERK, and NrF2 signaling pathways were shown to control AR-mediated SLC1A5 and GLS expression as well as glutamine metabolism in cisplatin-resistant chondrosarcoma (Fig. 7).